Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	48667
Country	Italy

Received	2019-04-29 01:02
Peer-Review Started	2019-05-09 03:09
To Make the First Decision	2019-06-05 06:11
Return for Revision	2019-06-17 03:35
Revised	2019-07-25 15:19
Second Decision	2019-08-23 09:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-08-28 01:18
Articles in Press	2019-08-28 01:18
Publication Fee Transferred
Edit the Manuscript by Language Editor	2019-09-11 19:56
Typeset the Manuscript	2019-10-14 09:34
Publish the Manuscript Online	2019-10-16 12:17

ISSN	1948-5204 (online)
Open Access	This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Targeted agents for second-line treatment of advanced hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Nicola Personeni, Tiziana Pressiani, Silvia Bozzarelli and Lorenza Rimassa
Funding Agency and Grant Number
Corresponding Author	Lorenza Rimassa, MD, Adjunct Professor, Chief Doctor, Humanitas Cancer Center, Humanitas Clinical and Research Center, IRCCS, via Manzoni 56, Rozzano 20089, Milan, Italy. lorenza.rimassa@cancercenter.humanitas.it
Key Words	Hepatocellular carcinoma; Advanced-metastatic; Second-line; Third-line; Regorafenib; Cabozantinib
Core Tip	During the last decade, sorafenib, a multikinase inhibitor, has emerged as the only systemic agent available for the treatment of patients with unresectable hepatocellular carcinoma. However, in recent years, lenvatinib, which is a different multikinase inhibitor, was shown to be non-inferior compared to sorafenib. Despite several negative phase III trials, novel drugs with similar, but not overlapping, properties have been recently shown to improve patient outcomes, thereby confirming the role of a sustained anti-angiogenic inhibition in further lines of treatment. Here, we will discuss the results of the positive phase III trials of regorafenib, cabozantinib, and ramucirumab in patients failing sorafenib.
Publish Date	2019-10-16 12:17
Citation	Personeni N, Pressiani T, Bozzarelli S, Rimassa L. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(10): 788-803
URL	https://www.wjgnet.com/1948-5204/full/v11/i10/788.htm
DOI	https://dx.doi.org/10.4251/wjgo.v11.i10.788

Full Article (PDF)	WJGO-11-788.pdf
Full Article (Word)	WJGO-11-788.docx
Manuscript File	FP6987_ce25_CE1MS-edit2_LR.docx
Answering Reviewers	48667-Answering reviewers.pdf
Audio Core Tip	48667-Audio-Core-Tip-revision.m4a
Conflict-of-Interest Disclosure Form	48667-Conflict-of-interest statement.pdf
Copyright License Agreement	48667-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	48667-Language certificate.pdf
Supplementary Material	48667-Supplementary material.zip
Peer-review Report	48667-Peer-review(s).pdf
Scientific Misconduct Check	48667-Scientific misconduct check.pdf
Scientific Editor Work List	48667-Scientific editor work list.pdf